A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Aileron Therapeutics, Inc.
Daiichi Sankyo
Affimed GmbH
Dizal Pharmaceuticals
Affimed GmbH
BeiGene
Takeda
HUYABIO International, LLC.
AstraZeneca
Kura Oncology, Inc.
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
University of Michigan Rogel Cancer Center
Solasia Pharma K.K.
Stanford University
University of Nebraska
Seagen Inc.
University of Nebraska
Weill Medical College of Cornell University
Therapeutic Advances in Childhood Leukemia Consortium
Asana BioSciences
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Spectrum Pharmaceuticals, Inc
National Institutes of Health Clinical Center (CC)
Spectrum Pharmaceuticals, Inc
Eisai Inc.
Fred Hutchinson Cancer Center
Mayo Clinic
University of California, San Francisco
Eisai Inc.
Celgene
Fred Hutchinson Cancer Center
Rhizen Pharmaceuticals SA
Acrotech Biopharma Inc.
Fondazione Italiana Linfomi - ETS
Mundipharma (China) Pharmaceutical Co. Ltd
Roswell Park Cancer Institute
University of Chicago
Case Comprehensive Cancer Center
Celgene
Wake Forest University Health Sciences
Takeda
Fred Hutchinson Cancer Center